Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats

被引:66
|
作者
Sancho, V
Trigo, MV
González, N
Valverde, I
Malaisse, WJ
Villanueva-Peñacarrillo, ML
机构
[1] Fdn Jimenez Diaz, Dept Metab Nutr & Hormones, E-28040 Madrid, Spain
[2] Free Univ Brussels, Lab Expt Hormonol, Brussels, Belgium
关键词
D O I
10.1677/jme.1.01747
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several kinases have been implicated in the metabolic response of human and rat myocytes to glucagon-like peptide-1 (GLP-1), exendin-4 (Ex-4) and exendin-9 (Ex-9). We have investigated, in isolated rat adipocytes, the changes caused by GLP-1, Ex-4 and Ex-9 compared with those provoked by insulin or glucagon, upon the activity of phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB), p42/44 MAP kinases (MAPKs) and p70s6 kinase (p70s6k), and the participation of these kinases and protein kinase C (PKC) in their action upon 2-deoxy-(D)-glucose uptake, lipolysis and lipogenesis. The study was conducted in normal rats, and extended to a streptozotocin-induced type-2 diabetic model (STZ-rats). The participation of distinct kinases was estimated by using potential kinase inhibitors, including wortmannin, PD98059, rapamycin, H-7 and RO31-8220. In normal rat adipocytes, GLP-1 and both exendins share with insulin an increasing action upon the activity of all kinases studied (except PKB), PI3K, p44 and p42 MAPKs and possibly PKC, all being required for their stimulating effect upon glucose uptake. Ex-4 and Ex-9, like GLP-1 and insulin, have lipogenic action, while only Ex-4 shares with GLP-1 its lipolytic effect which is antagonized by Ex-9. MAP kinases and PKC seem to have an essential role in the GLP-11 and Ex-4 lipolytic action, as does PI3K in that of Ex-4. An increase in PI3K and MAPKs activity for the lipogenic effect of Ex-4, Ex-9 and GLP-1 are required, and in the case of Ex-4 and Ex-9, a stimulation of p70s6k activity is also needed. In cells from STZ-rats the magnitude of the above parameters was, in general, comparable to that in normal animals, with some exceptions: basal PI3K activity and lipogenesis were higher, GLP-1, Ex-4 and Ex-9 failed to modify basal lipogenesis but increased PKB activity, insulin failed to affect the activity of MAPKs and the insulin-induced glucose uptake was impaired. The impaired insulin effects upon some of the variables in the STZ-rat, distinct from those of GLP-1 and exendins, adds knowledge to the mechanism of the beneficial action of GLP-1 and Ex-4 in diabetic states.
引用
收藏
页码:27 / 38
页数:12
相关论文
共 50 条
  • [41] Glucagon-like peptide-1 in type 2 diabetes:: the β-cell and beyond
    Nauck, Michael A.
    DIABETES OBESITY & METABOLISM, 2008, 10 : 2 - 13
  • [42] Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes
    Edwards, C. M. B.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (04) : 198 - 201
  • [43] Oral Delivery of Pentameric Glucagon-Like Peptide-1 by Recombinant Lactobacillus in Diabetic Rats
    Lin, Yin
    Krogh-Andersen, Kasper
    Pelletier, Julien
    Marcotte, Harold
    Ostenson, Claes-Goran
    Hammarstrom, Lennart
    PLOS ONE, 2016, 11 (09):
  • [44] Metformin effects on glucagon-like peptide-1 levels in obese diabetic and non diabetic patients
    Mannucci, E
    Bardini, G
    Tesi, F
    Ognibene, A
    Petracca, MG
    Ciani, S
    Brogi, M
    Cremasco, F
    Messeri, G
    Rotella, CM
    DIABETOLOGIA, 2002, 45 : A217 - A217
  • [45] Effects of glucagon and glucagon-like peptide-1 (GLP-1) on glycemic status and glucose production in the isletectomized diabetic goby.
    Haigwood, JT
    Perez, M
    Kelley, KM
    AMERICAN ZOOLOGIST, 2000, 40 (06): : 1038 - 1039
  • [46] Evolutionary or revolutionary? The transformative role of glucagon-like peptide-1 agonists in type-2 diabetes management
    Bockwoldt, Denise
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S1 - S1
  • [47] Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects
    Murakami, Takaaki
    Fujimoto, Hiroyuki
    Fujita, Naotaka
    Hamamatsu, Keita
    Yabe, Daisuke
    Inagaki, Nobuya
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (06) : 1448 - 1456
  • [48] Renal Extraction and Acute Effects of Glucagon-Like Peptide-1 on Central and Renal Hemodynamics in Type 2 Diabetic Males
    Asmar, Ali
    Simonsen, Lene
    Asmar, Meena
    Madsbad, Sten
    Holst, Jens Juul
    Frandsen, Erik
    Moro, Cedric
    Jonassen, Thomas
    Bulow, Jens
    DIABETES, 2015, 64 : A532 - A532
  • [49] GLUCAGON-LIKE PEPTIDE-1 AFFECTS GLUCOSE AND FAT METABOLISM IN THE LIVER VIA THE GLUCAGON RECEPTOR IN A RAT MODEL
    Ben Shlomo, Shani
    Zvibel, Isabel
    Halpern, Zamir
    Oren, Ran
    Fishman, Sigal
    HEPATOLOGY, 2009, 50 (04) : 374A - 374A
  • [50] Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?
    Ajith, Thekkuttuparambil A.
    CURRENT CLINICAL PHARMACOLOGY, 2019, 14 (03): : 242 - 243